Baird Reiterates Outperform Rating on Soleno Therapeutics Inc. (SLNO)

Baird analyst Brian Skorney reiterated an Outperform rating and $72.00 price target on Soleno Therapeutics Inc. (NASDAQ: SLNO)

The analyst commented: "Buyers on weakness from unrelated regulatory outcome. SLNO shares have traded, directionally, with APLT shares over the last couple of trading days, as they are both FDA regulatory plays on non-standard applications. Covering both, we think that they really are apples and oranges comparisons and would use the weakness in SLNO shares as a buying opportunity as we believe approval of DCCR really doesn't require much regulatory flexibility at all, where APLT was entirely reliant on FDA giving them a pass on the traditional statistical thresholds."

For an analyst ratings summary and ratings history on Soleno Therapeutics Inc. click here. For more ratings news on Soleno Therapeutics Inc. click here.

Shares of Soleno Therapeutics Inc. closed at $52.71 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Phillips 66, Marathon Merger Talks Collapsed - Semafor